Industry Updates: Sep 26, 2011

BrainStorm Receives Grant from Israel’s Office of the Chief Scientist

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell therapeutics targeting Central Nervous System (CNS) diseases, today announced that it received notice from Israel’s Office of the Chief Scientist (OCS) of its commitment to grant the Company approximately $1.1 million (NIS 3.8 million) in accordance with OCS requirements.

“We are grateful to the OCS for its continued support of BrainStorm. The non-dilutive capital that our company has received from the OCS helps advance our NurOwn™ technology as a new treatment paradigm for patients with Amyotrophic Lateral Sclerosis (ALS) and other neurological disorders,” said Chaim Lebovits, President of BrainStorm.